Evidence map›Paper›PMID 31129200›Full record

ArticleNeuroscience2019

FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.

Guadalupe Vidal-Martinez, Katherine Najera, Julie D Miranda, Carolina Gil-Tommee, Barbara Yang, Javier Vargas-Medrano, Valeria Diaz-Pacheco, Ruth G Perez

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. The effect of fingolimod (FTY720) protecting the retina of rats from light-induced retinal degeneration (LIRD).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Therapeutics in the Pipeline TargetingPharmacological reviews · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease.International journal of molecular sciences · 2020
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Guadalupe Vidal-MartinezDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Katherine NajeraDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Julie D MirandaDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Carolina Gil-TommeeDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Barbara YangDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Javier Vargas-MedranoDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
Valeria Diaz-PachecoDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA; BUILDingSCHOLARS Program, University of Texas at El Paso, El Paso, TX 79968, USA.
Ruth G PerezDepartment of Molecular and Translational Medicine, Center of Emphasis in Neurosciences, Graduate School of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA; BUILDingSCHOLARS Program, University of Texas at El Paso, El Paso, TX 79968, USA. Electronic address: ruth.g.perez@ttuhsc.edu.
Texas Tech University Health Sciences Center · USTexas Tech University · US

Funding

a-Synuclein and Dopamine: Implications of ParkinsonismR01NS042094 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PEREZ, RUTH G · 2002 to 2010
$2.0M
U.S./Costa Rica Neuropsychiatric Genetics Research Training ProgramD43TW008333 · FIC · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCAMILLA, MICHAEL A, THOMPSON, PETER M · 2009 to 2013
$890k
FIC NIH HHS D43 TW008333NINDS NIH HHS R01 NS042094
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive aging disorder that affects millions worldwide, thus, disease-modifying-therapies are urgently needed. PD pathology includes α-synuclein (aSyn) accumulation as synucleinopathy. Loss of GM1 gangliosides occurs in PD brain, which is modeled in GM2 synthase transgenic mice. GM2+/- mice have low, not absent GM1 and develop age-onset motor deficits, making them an excellent PD drug testing model. FTY720 (fingolimod) reduces synucleinopathy in A53T aSyn mice and motor dysfunction in 6-OHDA and rotenone PD models, but no one has tested FTY720 in mice that develop age-onset PD-like motor problems. We confirmed that GM2+/-mice had equivalent rotarod, hindlimb reflexes, and adhesive removal functions at 9 mo. From 11 mo, GM2+/- mice received oral FTY720 or vehicle 3x/week to 16 mo. As bladder problems occur in PD, we also assessed GM2+/- bladder function. This allowed us to demonstrate improved motor and bladder function in GM2+/- mice treated with FTY720. By immunoblot, FTY720 reduced levels of proNGF, a biomarker of bladder dysfunction. In humans with PD, arm swing becomes abnormal, and brachial plexus modulates arm swing. Ultrastructure of brachial plexus in wild type and GM2 transgenic mice confirmed abnormal myelination and axons in GM2 transgenics. FTY720 treated GM2+/- brachial plexus sustained myelin associated protein levels and reduced aggregated aSyn and PSer129 aSyn levels. FTY720 increases brain derived neurotrophic factor (BDNF) and we noted increased BDNF in GM2+/- brachial plexus and cerebellum, which contribute to rotarod performance. These findings provide further support for testing low dose FTY720 in patients with PD.

Indexed as

alpha-SynucleinAnimalsBehavior, AnimalBrainBrain-Derived Neurotrophic FactorFingolimod HydrochlorideMiceMice, TransgenicMotor SkillsN-AcetylgalactosaminyltransferasesParkinson Disease, SecondaryRotarod Performance TestSphingosine 1 Phosphate Receptor Modulatorsalpha-SynucleinBrain-Derived Neurotrophic FactorFingolimod HydrochlorideN-Acetylgalactosaminyltransferases(N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferaseSphingosine 1 Phosphate Receptor Modulatorsbrachial plexus synucleinopathyimproved bladder functionlow dose drugmotor improvementmyelination biomarker increasesneuroprotection

Identifiers

PMID31129200
PMCPMC6612448
OpenAlexW2946470952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.